Related references
Note: Only part of the references are listed.Effects of ischemic preconditioning on ischemia/reperfusion-induced arrhythmias by upregulatation of connexin 43 expression
Zhenguang Chen et al.
JOURNAL OF CARDIOTHORACIC SURGERY (2011)
Inhibition of p38 Mitogen-Activated Protein Kinase Reduces Inflammation After Coronary Vascular Injury in Humans
Lea Sarov-Blat et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
A Chemical Genetic Approach Reveals That p38α MAPK Activation by Diphosphorylation Aggravates Myocardial Infarction and Is Prevented by the Direct Binding of SB203580
Sarawut Kumphune et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The activation of p38alpha, and not p38beta, mitogen-activated protein kinase is required for ischemic preconditioning
Pierre Sicard et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
The as-yet unfulfilled promise of p38 MAPK inhibitors
Susan E. Sweeney
NATURE REVIEWS RHEUMATOLOGY (2009)
Intracellular signaling pathways control mitochondrial events associated with the development of ischemia/reperfusion-associated damage
Robert Sucher et al.
TRANSPLANT INTERNATIONAL (2009)
Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction
A. R. Kompa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction
Jay C. Sy et al.
NATURE MATERIALS (2008)
p38 mitogen-activated protein kinase inhibition decreases TNFalpha secretion and protects against left ventricular remodeling in rats with myocardial ischemia
Huiqiu Yin et al.
INFLAMMATION (2008)
Myocardial ischemia/reperfusion causes VDAC phosphorylation which is reduced by cardioprotection with a p38 MAP kinase inhibitor
Hansjorg Schwertz et al.
PROTEOMICS (2007)
Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease
James E. Clark et al.
PHARMACOLOGY & THERAPEUTICS (2007)
FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction
Felix B. Engel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Proapoptotic BCL-2 family members and mitochondrial dysfunction during ischemia/reperfusion injury, a study employing cardiac HL-1 cells and GFP biosensors
Nathan R. Brady et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2006)
C-phycocyanin protects against ischemia-reperfusion injury of heart through involvement of p38 MAPK and ERK signaling
M Khan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms
JK Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Inhibition of myocardial apoptosis by ischaemic and beta-adrenergic preconditioning is dependent on p38 MAPK
JA Moolman et al.
CARDIOVASCULAR DRUGS AND THERAPY (2006)
p38 mitogen activated protein kinase mediates both death signaling and functional depression in the heart
MJ Wang et al.
ANNALS OF THORACIC SURGERY (2005)
Role of F-actin organization in p38 MAP kinase-mediated apoptosis and necrosis in neonatal rat cardiomyocytes subjected to simulated ischemia and reoxygenation
T Okada et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion
RA Kaiser et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade
SL House et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Antimycin A induced cardioprotection is dependent on pre-ischemic p38-MAPK activation but independent of MKK3
AMN Kabir et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2005)
Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580
T Sumida et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
P38 MAP kinase mediates inflammatory cytokine induction in cardiomyocytes and extracellular matrix remodeling in heart
MX Li et al.
CIRCULATION (2005)
Inhibition of p38 mitogen-activated protein kinase protects the heart against cardiac remodeling in mice with heart failure resulting from myocardial infarction
YH Liu et al.
JOURNAL OF CARDIAC FAILURE (2005)
Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo
RA Kaiser et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Cell survival signalling in heart derived myofibroblasts induced by preconditioning and bradykinin: The role of p38 MAP kinase
M Cooper et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2004)
Impact of brief oxidant stress on primary adult cardiac fibroblasts
JT Colston et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Effects of adding p38 mitogen-activated protein-kinase inhibitor to Celsior solution in canine heart transplantation from non-heart-beating donors
N Koike et al.
TRANSPLANTATION (2004)
Inhibition of p38 MAPK activity falls to attenuate contractile dysfunction in a mouse model of low-flow ischemia
DA Gorog et al.
CARDIOVASCULAR RESEARCH (2004)
Myocardial protective effect of FR167653; a novel cytokine inhibitor in ischemic-reperfused rat heart
A Aleshin et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2004)
p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat
F See et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury
M Yada et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2004)
Feedback control of the protein kinase TAK1 by SAPK2a/p38α
PCF Cheung et al.
EMBO JOURNAL (2003)
Mechanism of p38 MAP kinase activation in vivo
D Brancho et al.
GENES & DEVELOPMENT (2003)
Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation - Evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia
M Tanno et al.
CIRCULATION RESEARCH (2003)
Hypoxia, angiotensin-II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes:: a role for p38 MAPK, Fas-L and cyclin D1
VG Sharov et al.
EUROPEAN JOURNAL OF HEART FAILURE (2003)
Effects of inhibition of myocardial extracellular-responsive kinase and p38 mitogen-activated protein kinase on mechanical function of rat hearts after prolonged hypothermic ischemia
AS Clanachan et al.
TRANSPLANTATION (2003)
p38 MAP kinase is a mediator of ischemic preconditioning in pigs
R Schulz et al.
CARDIOVASCULAR RESEARCH (2002)
MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α
BX Ge et al.
SCIENCE (2002)
P38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation
F Gao et al.
CARDIOVASCULAR RESEARCH (2002)
Signal transduction of ischemic preconditioning
R Schulz et al.
CARDIOVASCULAR RESEARCH (2001)
Antiischemic effects of SB203580 are mediated through the inhibition of p38α mitogen-activated protein kinase -: Evidence from ectopic expression of an inhibition-resistant kinase
JL Martin et al.
CIRCULATION RESEARCH (2001)
Role of G proteins and modulation of p38 MAPK activation in the protection by nitric oxide against ischemia-reoxygenation injury
RD Rakhit et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion
E Marais et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2001)
p38 MAPK activity is not increased early during sustained coronary artery occlusion in preconditioned versus control rabbit heart
A Gysembergh et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2001)
SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts
A Nakano et al.
BASIC RESEARCH IN CARDIOLOGY (2000)
The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical
MM Mocanu et al.
BASIC RESEARCH IN CARDIOLOGY (2000)
The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes
AT Saurin et al.
FASEB JOURNAL (2000)
Involvement of a p38 mitogen-activated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia
K Mackay et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2000)
Inhibition of p38 MAP kinase as a therapeutic strategy
JC Lee et al.
IMMUNOPHARMACOLOGY (2000)
Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death
M Barancik et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2000)
Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart
TL Yue et al.
CIRCULATION RESEARCH (2000)
The p38 signal transduction pathway - Activation and function
K Ono et al.
CELLULAR SIGNALLING (2000)
Share Paper
